JP2013526525A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526525A5
JP2013526525A5 JP2013510219A JP2013510219A JP2013526525A5 JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5 JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5
Authority
JP
Japan
Prior art keywords
day
pharmaceutical composition
composition according
isoindol
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526525A (ja
Filing date
Publication date
Priority claimed from US12/777,765 external-priority patent/US8404716B2/en
Application filed filed Critical
Publication of JP2013526525A publication Critical patent/JP2013526525A/ja
Publication of JP2013526525A5 publication Critical patent/JP2013526525A5/ja
Pending legal-status Critical Current

Links

JP2013510219A 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 Pending JP2013526525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/777,765 US8404716B2 (en) 2002-10-15 2010-05-11 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US12/777,765 2010-05-11
PCT/US2011/035822 WO2011143147A1 (en) 2010-05-11 2011-05-10 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine

Publications (2)

Publication Number Publication Date
JP2013526525A JP2013526525A (ja) 2013-06-24
JP2013526525A5 true JP2013526525A5 (enExample) 2014-04-17

Family

ID=44314968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510219A Pending JP2013526525A (ja) 2010-05-11 2011-05-10 レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Country Status (6)

Country Link
US (4) US8404716B2 (enExample)
EP (2) EP3219317A1 (enExample)
JP (1) JP2013526525A (enExample)
CN (1) CN103025330A (enExample)
AU (1) AU2011253161B2 (enExample)
WO (1) WO2011143147A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
EP2760456A1 (en) * 2011-09-26 2014-08-06 Celgene Corporation Combination therapy for chemoresistant cancers
KR102165348B1 (ko) 2012-05-09 2020-10-14 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
EP3171870B1 (en) 2014-07-24 2021-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
PT3182996T (pt) 2014-08-22 2023-03-21 Celgene Corp Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
WO2016133910A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
EP3442591A4 (en) * 2016-04-15 2019-11-20 Seattle Genetics, Inc. COMBINATIONS OF CD33 ANTIBODY-ACTIVE CONJUGATES WITH HYPOMETHYLATING AGENTS
EP3463463A4 (en) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
KR20190015300A (ko) 2016-06-06 2019-02-13 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-5-일)메틸)-2,2-다이플루오로아세트아마이드에 의한 혈액 악성종양의 치료
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
IL290857B2 (en) 2016-12-08 2023-03-01 Lixte Biotechnology Inc Oxabicycloheptanes for immune response modulation
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP7017638B2 (ja) 2018-02-07 2022-02-08 ラブレス バイオメディカル リサーチ インスティテュート 吸入可能な乾燥粉末シチジン類似体組成物及び癌への治療として使用する方法
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CN113056267A (zh) * 2018-08-26 2021-06-29 凯帝夫肿瘤科技有限公司 Plk1靶磷酸化状态以及用plk1抑制剂治疗癌症
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
KR20210097157A (ko) * 2018-11-30 2021-08-06 메이 파마, 아이엔씨. 고위험 및 초고위험 골수이형성 증후군(mds)을 위한 병용 요법
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP4470618A3 (en) 2019-03-06 2025-03-05 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN109771643A (zh) * 2019-03-06 2019-05-21 厦门大学附属中山医院 儿童地中海贫血干细胞移植预处理联合化疗剂
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CA3137594A1 (en) * 2019-04-22 2020-10-29 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents
EP4048668A4 (en) * 2019-10-21 2024-03-13 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
EP4048278B1 (en) * 2019-10-21 2023-11-01 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
KR20220093323A (ko) * 2019-11-05 2022-07-05 에프. 호프만-라 로슈 아게 HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
MX2023008091A (es) 2021-01-08 2023-07-14 Starton Therapeutics Inc Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.
WO2025024484A1 (en) * 2023-07-25 2025-01-30 Duke University Compositions and methods for treating blood cancer

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228601A (en) 1964-02-20 1966-01-11 Monarch Marking Systems Inc Controls for marking machine
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
JPH05503302A (ja) 1990-10-12 1993-06-03 アムジエン・インコーポレーテツド 巨核球成熟因子
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5641758A (en) * 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6432924B1 (en) * 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996013790A1 (en) 1994-10-28 1996-05-09 Advanced Health Med-E-Systems Corporation Prescription management system
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2262906C (en) * 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
DK1920773T3 (da) * 1996-11-05 2011-03-28 Childrens Medical Center Thalidomid og dexamethason til behandling af tumorer
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
AU8909898A (en) 1997-08-22 1999-03-16 Deka Products Limited Partnership Health care system and method for physician order entry
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
BR9908811A (pt) * 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
ATE306469T1 (de) * 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU6015400A (en) * 1999-07-16 2001-02-05 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
MXPA02007254A (es) * 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
AU2001249755A1 (en) * 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
DE60118547T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2002015926A1 (en) 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
ATE450529T1 (de) * 2001-02-27 2009-12-15 Governement Of The United Stat Analoga von thalidomid als angiogeneseinhibitoren
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
US20030220254A1 (en) * 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2915533B1 (en) 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
CN1668296A (zh) 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
MXPA06011798A (es) 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
EP1744748A4 (en) 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008027049A1 (en) 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US20080057086A1 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
EP2695609B1 (en) * 2008-05-15 2019-12-11 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Similar Documents

Publication Publication Date Title
JP2013526525A5 (enExample)
JP2009545600A5 (enExample)
JP2007045839A5 (enExample)
Rothenberg Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond
TWI782906B (zh) 惡性腫瘤治療用製劑及組合物
EP3194368B1 (en) Benzo-heterocyclic compounds and their applications
JP2014065696A5 (enExample)
JP2014040437A5 (enExample)
JP2006507271A5 (enExample)
JP2005530784A5 (enExample)
JP2014532704A5 (enExample)
JP2012180381A5 (enExample)
JP2013526525A (ja) レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法
JP2017524031A5 (enExample)
JP2010520289A5 (enExample)
JP2012067116A5 (enExample)
CN103596935A (zh) Cxcr4拮抗剂的用途
IL168061A (en) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)- piperidine- 2, 6-dione for use in a medicament for treating and managing myelodysplastic syndromes
JP2011500805A5 (enExample)
JP2009539994A5 (enExample)
TWI741286B (zh) 治療癌症之方法
JP2010528091A5 (enExample)
CN111870600B (zh) 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用
CN101610776A (zh) 包含CNDAC(2′-氰基-2′-脱氧-N4 -棕榈酰基-1-β-D-阿拉伯呋喃糖基-胞嘧啶)和细胞毒剂的组合
CA2782146A1 (en) Small pyrimidine derivatives and methods of use thereof